Do short periods of poor adherence with rhGH impact height?
Less than 3 months of poor adherence with recombinant human growth hormone (rhGH) does not appear to impact height change as a standard deviation score (SDS), although poor adherence leading to a low true daily GH dose resulted in low yearly height gain, according to a 12-month treatment model.
The mean daily rhGH dose and mean number of injections per week were analyzed in 220 children receiving rhGH injections.
The mean ± SD age was 9.8 ± 3.7 years (females: 47%, prepubertal: 86%) and the mean height was -2.28 ± 0.92 SDS at the initiation of treatment. There was a mean treatment duration of 3.2 ± 1.1 years. Patients were GH-deficient (n = 122), small for gestational age (n = 79), and had Turner syndrome (n = 19).
Over 12-month periods, a mean daily dose <0.03 mg/kg.d was associated with a 20% lower mean yearly height gain SDS when<3 injections/week were received (vs >5 injections/week). However, a mean daily dose of >0.03 mg/kg.d with<3 injections/week was not associated with a lower yearly height gain SDS (vs >5 injections/week).
When treatment was computed over 3-month periods, yearly height gain SDS was not impacted by changes in the daily rhGH dose or the number of injections per week.
Coutant R, Nicolino M, Cammas B, et al. Yearly Height Gain Is Dependent on the Truly Received Dose of Growth Hormone and the Duration of Periods of Poor Adherence: Practical Lessons From the French Easypod™ Connect Multicenter Observational Study. Front Endocrinol (Lausanne). 2022;12:790169. doi: 10.3389/fendo.2021.790169. PMID: 35126310; PMCID: PMC8812007.